{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:41:29Z","timestamp":1761129689151,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.phrs.2019.104556","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:51:28Z","timestamp":1574682688000},"page":"104556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia"],"prefix":"10.1016","volume":"151","author":[{"given":"Catalina M.","family":"Perell\u00f3-Reus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Catal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liska","family":"Caviedes-C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerea","family":"Vega-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Cam\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"P\u00e9rez-Torras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00e7al","family":"Pastor-Anglada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.phrs.2019.104556_bib0005","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2019.104556_bib0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/gcc.20508","article-title":"FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns","volume":"47","author":"Andersson","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2019.104556_bib0015","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2003-06-1845","article-title":"Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia","volume":"103","author":"Ozeki","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.phrs.2019.104556_bib0020","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1182\/blood-2011-05-353185","article-title":"Society of Pediatric, Oncology, Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia","volume":"118","author":"Staffas","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2019.104556_bib0025","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.11220","article-title":"D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia","volume":"92","author":"Stam","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.phrs.2019.104556_bib0030","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","article-title":"Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia","volume":"106","author":"Stam","year":"2005","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.phrs.2019.104556_bib0035","doi-asserted-by":"crossref","first-page":"49786","DOI":"10.18632\/oncotarget.10448","article-title":"FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia","volume":"7","author":"Catala","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.phrs.2019.104556_bib0040","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2004-01-0388","article-title":"In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects","volume":"104","author":"Levis","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2019.104556_bib0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04386.x","article-title":"Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine","volume":"122","author":"Galmarini","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104556_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.phrs.2019.104556_bib0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-006-0195-8","article-title":"Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells","volume":"58","author":"Jordheim","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"34","key":"10.1016\/j.phrs.2019.104556_bib0060","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.2174\/0929867311320340008","article-title":"Therapeutic perspectives for cN-II in cancer","volume":"20","author":"Jordheim","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2019.104556_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2015.01.010","article-title":"The purine analog fludarabine acts as a cytosolic 5\u2019-nucleotidase II inhibitor","volume":"94","author":"Cividini","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104556_bib0070","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.gastro.2012.06.006","article-title":"Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma","volume":"143","author":"Marechal","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2019.104556_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fphar.2015.00013","article-title":"Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets","volume":"6","author":"Pastor-Anglada","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104556_bib0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104556_bib0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat. Med."},{"issue":"7377","key":"10.1016\/j.phrs.2019.104556_bib0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.phrs.2019.104556_bib0095","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","article-title":"SAMHD1 protects cancer cells from various nucleoside-based antimetabolites","volume":"16","author":"Herold","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.phrs.2019.104556_bib0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2017.05.001","article-title":"With me or against me: tumor suppressor and drug resistance activities of SAMHD1","volume":"52","author":"Herold","year":"2017","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104556_bib0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-015-2921-6","article-title":"The druggability of intracellular nucleotide-degrading enzymes","volume":"77","author":"Rampazzo","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104556_bib0110","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2002-07-2236","article-title":"Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia","volume":"101","author":"Molina-Arcas","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.phrs.2019.104556_bib0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0165-6147(98)01253-X","article-title":"Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies","volume":"19","author":"Pastor-Anglada","year":"1998","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2019.104556_bib0120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","article-title":"Standing the test of time: targeting thymidylate biosynthesis in cancer therapy","volume":"11","author":"Wilson","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Pt A","key":"10.1016\/j.phrs.2019.104556_bib0125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.phrs.2016.09.007","article-title":"Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: a transportome approach","volume":"113","author":"Grane-Boladeras","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"6274","key":"10.1016\/j.phrs.2019.104556_bib0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1126\/science.aac6054","article-title":"Spatial colocalization and functional link of purinosomes with mitochondria","volume":"351","author":"French","year":"2016","journal-title":"Science"},{"issue":"6125","key":"10.1016\/j.phrs.2019.104556_bib0135","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science"},{"issue":"6125","key":"10.1016\/j.phrs.2019.104556_bib0140","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.1228771","article-title":"Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis","volume":"339","author":"Robitaille","year":"2013","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.phrs.2019.104556_bib0145","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1084\/jem.20121061","article-title":"Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress","volume":"209","author":"Austin","year":"2012","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.phrs.2019.104556_bib0150","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1073\/pnas.0913900107","article-title":"Requirement for deoxycytidine kinase in T and B lymphocyte development","volume":"107","author":"Toy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2019.104556_bib0155","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/ncomms8389","article-title":"Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities","volume":"6","author":"Kollareddy","year":"2015","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.phrs.2019.104556_bib0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.celrep.2015.06.069","article-title":"Chronic FLT3-ITD signaling in acute myeloid leukemia is connected to a specific chromatin signature","volume":"12","author":"Cauchy","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.phrs.2019.104556_bib0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","article-title":"FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2019.104556_bib0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.tim.2015.08.002","article-title":"SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction","volume":"23","author":"Ballana","year":"2015","journal-title":"Trends Microbiol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104556_bib0175","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.celrep.2013.03.017","article-title":"Phosphorylation of SAMHD1 by cyclin A2\/CDK1 regulates its restriction activity toward HIV-1","volume":"3","author":"Cribier","year":"2013","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.phrs.2019.104556_bib0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.chom.2013.03.005","article-title":"The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation","volume":"13","author":"White","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"9","key":"10.1016\/j.phrs.2019.104556_bib0185","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/15384101.2018.1480216","article-title":"The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592","volume":"17","author":"Tramentozzi","year":"2018","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.phrs.2019.104556_bib0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158290","article-title":"Internal tandem duplication in FLT3 attenuates proliferation and regulates resistance to the FLT3 inhibitor AC220 by modulating p21Cdkn1a and Pbx1 in hematopoietic cells","volume":"11","author":"Abe","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.phrs.2019.104556_bib0195","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40265-017-0779-0","article-title":"Midostaurin: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.phrs.2019.104556_bib0200","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819315865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819315865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:06:09Z","timestamp":1760911569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819315865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":40,"alternative-id":["S1043661819315865"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104556","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104556"}}